AbbVie (NYSE: ABBV) reported Q2 EPS of $1.42, $0.02 better than the analyst estimate of $1.40. Revenue for the quarter came in at $6.94 billion versus the consensus estimate of $6.92 billion.

GUIDANCE:

AbbVie sees FY2017 EPS of $5.44-$5.54, versus the consensus of $5.53.

For earnings history and earnings-related data on AbbVie (ABBV) click here.